Compare DexCom, Inc. (DXCM) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Marqeta Inc — how do they compare? DexCom, Inc. trades at $90.39 (market cap $33.79B), while Marqeta Inc trades at $15.46 (market cap $1.62B). The key difference: DexCom, Inc. is far larger — about 20.9× Marqeta Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | MQ | |
|---|---|---|
Market Cap | $33.79B | $1.62B |
Sector | Health | Technology |
52-Week High | $89.53 | $26.00 |
52-Week Low | $54.84 | $15.04 |
Enterprise Value | $33.24B | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
MQ trades at $15.59, down slightly by 0.06%. The stock exhibits a bearish technical signal with strong selling pressure on moving averages. Fundamentally, the company shows improving revenue trends, with 2026 revenue projected at $677 million and a return to positive net income. Recent partnerships with Google and Riskified highlight strategic growth initiatives in digital payments and fraud prevention.
MQ's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but high valuation ratios and past earnings volatility present risks. Analyst consensus is a 'Hold' with a $19 price target, suggesting moderate upside potential from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
